1. Home
  2. PSTV vs LSBPW Comparison

PSTV vs LSBPW Comparison

Compare PSTV & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • LSBPW
  • Stock Information
  • Founded
  • PSTV 1996
  • LSBPW N/A
  • Country
  • PSTV United States
  • LSBPW China
  • Employees
  • PSTV N/A
  • LSBPW N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • LSBPW Biotechnology: Pharmaceutical Preparations
  • Sector
  • PSTV Health Care
  • LSBPW Health Care
  • Exchange
  • PSTV Nasdaq
  • LSBPW Nasdaq
  • Market Cap
  • PSTV 9.9M
  • LSBPW 7.4M
  • IPO Year
  • PSTV N/A
  • LSBPW N/A
  • Fundamental
  • Price
  • PSTV $1.74
  • LSBPW $0.08
  • Analyst Decision
  • PSTV Strong Buy
  • LSBPW
  • Analyst Count
  • PSTV 1
  • LSBPW 0
  • Target Price
  • PSTV $8.00
  • LSBPW N/A
  • AVG Volume (30 Days)
  • PSTV 57.2K
  • LSBPW N/A
  • Earning Date
  • PSTV 08-12-2024
  • LSBPW N/A
  • Dividend Yield
  • PSTV N/A
  • LSBPW N/A
  • EPS Growth
  • PSTV N/A
  • LSBPW N/A
  • EPS
  • PSTV N/A
  • LSBPW N/A
  • Revenue
  • PSTV $6,084,000.00
  • LSBPW N/A
  • Revenue This Year
  • PSTV $5.21
  • LSBPW N/A
  • Revenue Next Year
  • PSTV N/A
  • LSBPW N/A
  • P/E Ratio
  • PSTV N/A
  • LSBPW N/A
  • Revenue Growth
  • PSTV 733.42
  • LSBPW N/A
  • 52 Week Low
  • PSTV $0.97
  • LSBPW N/A
  • 52 Week High
  • PSTV $3.21
  • LSBPW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 47.37
  • LSBPW N/A
  • Support Level
  • PSTV $1.70
  • LSBPW N/A
  • Resistance Level
  • PSTV $2.07
  • LSBPW N/A
  • Average True Range (ATR)
  • PSTV 0.17
  • LSBPW 0.00
  • MACD
  • PSTV 0.03
  • LSBPW 0.00
  • Stochastic Oscillator
  • PSTV 50.75
  • LSBPW 0.00

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: